World J Hepatol. Nov 27, 2026; 18(11): 125639 Published online Nov 27, 2026. doi: 10.4254/wjh.125639
Hepatocyte identity across steatosis-resolving therapies: Integrative transcriptomic and functional assessment
Batool Mrayyan, Mustafa Salaho
Batool Mrayyan, Mustafa Salaho, Faculty of Pharmacy, Isra University, Amman 11622, Jordan
Author contributions: Mrayyan B wrote the first draft of the manuscript, and was responsible for study conceptualization, methodology, data curation, formal analysis and visualization; Salaho M supervised the study, performed validation and result interpretation, and participated in manuscript review and editing; and all authors read and approved the final manuscript.
AI contribution statement: All scientific content, analyses, interpretations, and conclusions were independently verified and approved by the authors.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Batool Mrayyan, Researcher, Faculty of Pharmacy, Isra University, Queen Alia Airport Road, Amman 11622, Jordan. ah0406@iu.edu.jo
Received: July 16, 2026 Revised: August 8, 2026 Accepted: October 16, 2026 Published online: November 27, 2026 Processing time: 129 Days and 10.8 Hours
Core Tip
Core Tip: This study presents a comprehensive transcriptomic framework to evaluate steatosis-targeting therapies by analyzing steatosis-related gene modulation, hepatocyte identity, cellular stress, and donor consistency, going beyond lipid reduction alone. Among the five therapies studied, diacylglycerol acyltransferase 2 inhibition demonstrated the most favorable relative exploratory profile. We further explored the association of the diacylglycerol acyltransferase 2 inhibition-derived signature with the transcriptional state of hepatocytes by exploratory single-cell analysis. However, these results remain hypothesis-generating due to the limited number of donors, the post hoc selection of signatures, and the pseudoreplication of single cells.